BioAge Discovers Key Pathway and Identifies Promising Phase 2 Ready Drug to Treat and Reverse Immune Aging, a Root Cause of COVID-19 Morbidity and Mortality in Older Patients
25 août 2020 08h00 HE
|
BioAge Labs, Inc.
BioAge Plans Phase 2 Clinical trial in Hospitalized COVID-19 Patients Clinical development plan supported by potent inhibition of PGD2 DP1 Receptor by BGE-175, activating immune-modulating...
BioAge Signs Exclusive License Agreement with Taisho to Develop and Commercialize Taisho’s Phase 1 HIF-PH Inhibitor to Treat Aging
29 avr. 2020 22h00 HE
|
BioAge Labs, Inc.
RICHMOND, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- BioAge Labs, Inc., a biotechnology company developing medicines to treat aging and age-related diseases, today announced that it has entered into...